Evidence map›Paper›PMID 41193656›Full record

ArticleNature genetics2025

Epigenetically driven and early immune evasion in colorectal cancer evolution.

Eszter Lakatos, Vinaya Gunasri, Luis Zapata, Jacob Househam, Timon Heide, Nicholas Trahearn, Ottilie Swinyard, Luis Cisneros, Claire Lynn, Maximilian Mossner and 12 more

Abstract read
In one paragraph

Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Eszter Lakatos *Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. eszter.lakatos@chalmers.se.ORCID http://orcid.org/0000-0002-7221-6850
Vinaya Gunasri *UCL Cancer Institute, University College London, London, UK.
Luis ZapataCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Jacob HousehamCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-3199-336X
Timon HeideCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1386-7469
Nicholas TrahearnCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-8596-0996
Ottilie SwinyardCentre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Luis CisnerosArizona Cancer Evolution Center, Biodesign Institute and School of Life Sciences Arizona State University, Tempe, AZ, USA.ORCID http://orcid.org/0000-0002-7890-1269
Claire LynnCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Maximilian MossnerCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Chris KimberleyCentre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Inmaculada SpiteriCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0002-1097-8972
George D CresswellCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0003-3303-068X
Gerard Llibre-PalomarCentre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-4741-3473
Miriam MitchisonHistopathology Department, University College London Hospitals NHS Foundation Trust, London, UK.
Carlo C MaleyArizona Cancer Evolution Center, Biodesign Institute and School of Life Sciences Arizona State University, Tempe, AZ, USA.ORCID http://orcid.org/0000-0002-0745-7076
Marnix JansenUCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0003-0645-564X
Manuel Rodriguez-JustoUCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0001-5007-1761
John BridgewaterUCL Cancer Institute, University College London, London, UK.
Ann-Marie BakerCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.ORCID http://orcid.org/0000-0001-8905-9137
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK. andrea.sottoriva@fht.org.ORCID http://orcid.org/0000-0001-6709-9533
Trevor A GrahamCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK. trevor.graham@icr.ac.uk.ORCID http://orcid.org/0000-0001-9582-1597

Funding

Molecular, Cellular and Tissue Characterization UnitU2CCA233254 · NCI · DUKE UNIVERSITY · PI HWANG, E.SHELLEY · 2018 to 2023
$11.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
Modeling Neoplastic Progression in Barrett's Esophagus - Renewal -2R01CA140657 · NCI · WISTAR INSTITUTE · PI Carlo Maley · 2009 to 2026
$5.0M
A cell-cycle induced genetic recorder for simultaneous recovery of cell divisions and lineageR21CA257980 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MALEY, CARLO, WEISS, RON · 2022 to 2023
$576k
NCI NIH HHS R01 CA140657NCI NIH HHS R21 CA257980NCI NIH HHS U2C CA233254NCI NIH HHS U54 CA217376Pathological Society of Great Britain and Ireland JSPS/CLG/1022/01Vetenskapsrådet (Swedish Research Council) VR2024-04145Wellcome TrustWellcome Trust (Wellcome) 202778/B/16/ZWellcome Trust (Wellcome) 202778/Z/16/Z
6 · The paper itself

Abstract

Immune system control is a principal hurdle in cancer evolution. The temporal dynamics of immune evasion remain incompletely characterized, and how immune-mediated selection interrelates with epigenome alteration is unclear. Here we infer the genome- and epigenome-driven evolutionary dynamics of tumor-immune coevolution within primary colorectal cancers (CRCs). We utilize a multiregion multiomic dataset of matched genome, transcriptome and chromatin accessibility profiling from 495 single glands (from 29 CRCs) supplemented with high-resolution spatially resolved neoantigen sequencing data and multiplexed imaging of the tumor microenvironment from 82 microbiopsies within 11 CRCs. Somatic chromatin accessibility alterations contribute to accessibility loss of antigen-presenting genes and silencing of neoantigens. Immune escape and exclusion occur at the outset of CRC formation, and later intratumoral differences in immuno-editing are negligible or exclusive to sites of invasion. Collectively, immune evasion in CRC follows a 'Big Bang' evolutionary pattern, whereby it is acquired close to transformation and defines subsequent cancer-immune evolution.

Indexed as

Colorectal NeoplasmsEpigenesis, GeneticTumor EscapeAntigen PresentationDatasets as TopicHumansMultiomicsNeoplasm InvasivenessTranscription, Genetic

Identifiers

PMID41193656
PMCPMC12695633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.